Empery Asset Mgmt. Holds 4.5M Shares of X4 Pharmaceuticals

TL;DR

**Empery Asset Management still holds 4.5M shares of X4 Pharma, signaling continued institutional interest.**

AI Summary

Empery Asset Management, LP, a Delaware-based investment firm, filed an amended SC 13G/A on January 8, 2024, disclosing its beneficial ownership in X4 Pharmaceuticals, Inc. As of December 31, 2023, Empery Asset Management holds shared voting power over 4,549,605 shares of X4 Pharmaceuticals' Common Stock. This filing indicates a significant institutional stake, which can influence the stock's stability and investor confidence, as large holders often signal long-term interest.

Why It Matters

This filing shows a major institutional investor, Empery Asset Management, LP, maintains a substantial stake in X4 Pharmaceuticals, which can be a vote of confidence or a signal of potential future influence on company decisions.

Risk Assessment

Risk Level: low — The filing indicates a stable, significant institutional holding, which generally reduces volatility and provides a baseline of investor confidence.

Analyst Insight

Investors should note the continued significant institutional ownership by Empery Asset Management, LP, which could imply a degree of stability or long-term interest in X4 Pharmaceuticals, Inc. This information is useful for assessing institutional confidence in the company.

Key Numbers

• 4,549,605 shares — Shared Voting Power (The number of Common Stock shares of X4 Pharmaceuticals, Inc. over which Empery Asset Management, LP has shared voting power as of December 31, 2023.)
• $0.001 — Par Value (The par value per share of X4 Pharmaceuticals, Inc. Common Stock.)

Key Players & Entities

• Empery Asset Management, LP (company) — the reporting person holding shares in X4 Pharmaceuticals, Inc.
• X4 Pharmaceuticals, Inc. (company) — the subject company whose securities are being reported.
• Delaware (company) — place of organization for Empery Asset Management, LP
• December 31, 2023 (date) — the date of the event requiring the filing of this statement
• January 8, 2024 (date) — the filing date of the SC 13G/A

Forward-Looking Statements

• Empery Asset Management, LP will maintain a significant stake in X4 Pharmaceuticals, Inc. for the foreseeable future. (Empery Asset Management, LP) — medium confidence, target: 2025-01-08

FAQ

Key Financial Figures

• $0.001 — me of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 98420

Filing Documents

• p24-0029sc13ga.htm (SC 13G/A) — 75KB
• 0000902664-24-000073.txt ( ) — 76KB

(a)

Item 1(a). NAME OF ISSUER: The name of the issuer is X4 Pharmaceuticals, Inc. (the " Company ").

(b)

Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES: The Company's principal executive offices are located at 61 North Beacon Street, 4 th Floor, Boston, MA 02134.

(a)

Item 2(a). NAME OF PERSON FILING: This statement is filed by the entities and persons listed below, who are collectively referred to herein as " Reporting Persons ," with respect to the Common Stock (as defined in Item 2(d) below) of the Company: Investment Manager (i)Empery Asset Management, LP (the " Investment Manager "), with respect to the shares of Common Stock held by, and underlying the Reported Warrants (as defined below) held by, funds to which the Investment Manager serves as investment manager (the " Empery Funds "). Reporting Individuals (ii)Mr. Ryan M. Lane (" Mr. Lane "), with respect to the shares of Common Stock held by, and underlying the Reported Warrants held by, the Empery Funds. (iii)Mr. Martin D. Hoe (" Mr. Hoe "), with respect to the shares of Common Stock held by, and underlying the Reported Warrants held by, the Empery Funds. The Investment Manager serves as the investment manager to each of the Empery Funds. Each of Mr. Lane and Mr. Hoe (the " Reporting Individuals ") is a Managing Member of Empery AM GP, LLC (the " General Partner "), the general partner of the Investment Manager.

(b)

Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE: The address of the business office of each of the Reporting Persons is: 1 Rockefeller Plaza, Suite 1205 New York, New York 10020

(c)

Item 2(c). CITIZENSHIP: Citizenship is set forth in Row 4 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person. CUSIP No. 98420X103 13G Page 6 of 9 Pages

(d)

Item 2(d). TITLE OF CLASS OF SECURITIES: Common Stock, par value $0.001 (the " Common Stock ")

(e)

Item 2(e). CUSIP NUMBER: 98420X103 Item 3. IF THIS STATEMENT IS FILED PURSUANT TO RULES 13d-1(b) OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A: (a) ¨ Broker or dealer registered under Section 15 of the Act, (b) ¨ Bank as defined in Section 3(a)(6) of the Act, (c) ¨ Insurance Company as defined in Section 3(a)(19) of the Act, (d) ¨ Investment Company registered under Section 8 of the Investment Company Act of 1940, (e) x Investment Adviser registered under Section 203 of the Investment Advisers Act of 1940, (f) ¨ Employee Benefit Plan or Endowment Fund in accordance with Rule 13d1(b)(1)(ii)(F), (g) ¨ Parent Holding Company or control person in accordance with Rule 13d1(b)(1)(ii)(G), (h) ¨ Savings Association as defined in Section 3(b) of the Federal Deposit Insurance Act, (i) ¨ Church Plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940, (j) ¨ A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J); (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution: ___________________________ CUSIP No. 98420X103 13G Page 7 of 9 Pages Item 4. The information as of the date of the event which requires filing of this statement required by Items 4(a) – (c) is set forth in Rows 5 – 11 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person. The percentage set forth in Row 11 of the cover page for each Reporting Person is based on 167,291,209 shares of Common Stock issued and outstanding as of November 7, 2023, as represented in the Company's Quarterly Report on Form 10-Q filed on November 9, 2023 and assumes the exercise of the Company's reported warrants (the " Reported Warrants ") subject to th

SIGNATURES

SIGNATURES After reasonable inquiry and to the best of our knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct. DATED: January 8, 2024 EMPERY ASSET MANAGEMENT, LP By: EMPERY AM GP, LLC, its General Partner By: _ /s/ Ryan M. Lane ___________________ Name: Ryan M. Lane Title: Managing Member _ /s/ Ryan M. Lane ______________________ Ryan M. Lane _ /s/ Martin D. Hoe ______________________ Martin D. Hoe

View Full Filing

View this SC 13G/A filing on SEC EDGAR